Long-term primary cultures of human adult atrial cardiac myocytes: Cell viability, structural properties and BNP secretion in vitro

Bistola, Vasiliki; Nikolopoulou, Μarilena; Derventzi, Anastasia; Kataki, Agapi; Sfyras, Nikolaos; Nikou, Niki; Toutouza, Marina; Toutouzas, Pavlos; Stefanadis, Christodoulos; Konstadoulakis, Manousos M.

doi:10.1016/j.ijcard.2007.10.058

Cited by 21 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 As shown in previous studies, extended culture of cardiomyocytes is difficult. 3 The presence of supporting cells, such as cardiac fibroblasts, smooth muscle cells, and endothelial cells, could be beneficial to the survival of the culture and would represent a more physiologically-relevant environment compared to native heart tissue. Cardiac fibroblast, smooth muscle cells, and endothelial cells within the culture could have directed AFSC differentiation through secreted factors and mechanotransduction separately from the progenitor populations.…”

Section: Discussionmentioning

confidence: 99%

“…Enzymatic digestion of the samples was adapted from literature. 3,14 Briefly, tissue samples were incubated in supplemented Krebs-Ringer solution (10mM HEPES (Sigma-Aldrich, St. Louis, MO, USA), 129 mM NaCl (Fisher Scientific, Waltham, MA, USA), 4.7 nM KCl (Fisher Scientific), 1.2 mM KH 2 PO 4 (Sigma-Aldrich), 1.2 mM MgSO 4 *7H 2 O (Sigma-Aldrich), 5 mM NaHCO 3 (Sigma-Aldrich), 5.5 glucose (Sigma-Aldrich), 2% BSA (EMD Chemicals, Gibbstown, NJ, USA), 20 mM taurine (Sigma-Aldrich), 2 mM L-carnitine (Sigma-Aldrich), 5mM creatine (Sigma-Aldrich)) with neutral protease (Worthington, Lakewood, NJ, USA). The protease solution was then brought to 37°C for 15 minutes in a stir flask.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Amniotic Fluid-Derived Stem Cells Demonstrated Cardiogenic Potential in Indirect Co-culture with Human Cardiac Cells

et al. 2014

View full text Add to dashboard Cite

Amniotic fluid-derived stem cells (AFSC) have been shown to be broadly multipotent and non-tumorogenic. Previous studies of direct mixing of AFSC and neonatal rat ventricle myocytes indicated evidence of AFSC cardiogenesis. In this study, we examined human AFSC cardiogenic potential in indirect co-culture with human cardiac cells in conditions that eliminated the possibility of cell fusion. Human AFSC in contact with human cardiac cells showed expression of cardiac troponin T (cTnT) in immunohistochemistry, and no evidence of cell fusion were found through fluorescent in situ hybridization. When indirectly co-cultured with cardiac cells, human AFSC in contact with cardiac cells across a thin porous membrane showed a statistically significant increase in cTnT expression compared to non-contact conditions but lacked upregulation of calcium modulating proteins and did not have functional or morphological characteristics of mature cardiomyocytes. This suggests that contact is a necessary but not sufficient condition for AFSC cardiac differentiation in co-culture with cardiac cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Amniotic Fluid-Derived Stem Cells Demonstrated Cardiogenic Potential in Indirect Co-culture with Human Cardiac Cells

et al. 2014

View full text Add to dashboard Cite

show abstract

“…These cells maintain their morphological integrity, possess all of the mature cardiac ion channels to detect any multi-channel effects, and function electrophysiologically similar to native environment [15–17]. In practice, their utility in nonclinical drug testing has been nonexistent due to a combination of scarcity of human cardiac tissue donors and technical difficulties such as limited number of passages and rapid de-differentiation in culture [18].…”

Section: The Current Standard For Nonclinical Testing: a Moving Targementioning

confidence: 99%

21st Century Cardio-Oncology

Sheng

Amiri‐Kordestani

Palmby

et al. 2016

JACC: Basic to Translational Science

View full text Add to dashboard Cite

Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than traditional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies. There is a growing need for better testing platforms, both for CV toxicity screening, as well as for elucidating mechanisms of cardiotoxicities of approved cancer therapies. This review discusses the utility of nonclinical models (in vitro, in vivo, & in silico) available and highlights recent advancements in modalities like human stem cell-derived cardiomyocytes for developing more comprehensive cardiotoxicity testing and new means of cardioprotection with targeted anticancer therapies.

show abstract

“…Cardiomyocytes, especially harvested from adult heart, have been found to possess a very limited proliferation capacity and could not be propagated as a cell line [79]. Repeated isolation of primary tissue is therefore necessary for in vitro functional and cytotoxicity analyses employing this cell type.…”

Section: Human Esc and Cardiotoxicitymentioning

confidence: 99%

Stem Cells in Pharmaceutical Biotechnology

Zuba‐Surma

Józkowicz²,

Dulak³

2011

CPB

View full text Add to dashboard Cite

Multiple populations of stem cells have been indicated to potentially participate in regeneration of injured organs. Especially, embryonic stem cells (ESC) and recently inducible pluripotent stem cells (iPS) receive a marked attention from scientists and clinicians for regenerative medicine because of their high proliferative and differentiation capacities. Despite that ESC and iPS cells are expected to give rise into multiple regenerative applications when their side effects are overcame during appropriate preparation procedures, in fact their most recent application of human ESC may, however, reside in their use as a tool in drug development and disease modeling. This review focuses on the applications of stem cells in pharmaceutical biotechnology. We discuss possible relevance of pluripotent cell stem populations in developing physiological models for any human tissue cell type useful for pharmacological, metabolic and toxicity evaluation necessary in the earliest steps of drug development. The present models applied for preclinical drug testing consist of primary cells or immortalized cell lines that show limitations in terms of accessibility or relevance to their in vivo counterparts. The availability of renewable human cells with functional similarities to their in vivo counterparts is the first landmark for a new generation of cell-based assays. We discuss the approaches for using stem cells as valuable physiological targets of drug activity which may increase the strength of target validation and efficacy potentially resulting in introducing new safer remedies into clinical trials and the marketplace. Moreover, we discuss the possible applications of stem cells for elucidating mechanisms of disease pathogenesis. The knowledge about the mechanisms governing the development and progression of multitude disorders which would come from the cellular models established based on stem cells, may give rise to new therapeutical strategies for such diseases. All together, the applications of various cell types derived from patient specific pluripotent stem cells may lead to targeted drug and cellular therapies for certain individuals.

show abstract

Long-term primary cultures of human adult atrial cardiac myocytes: Cell viability, structural properties and BNP secretion in vitro

Cited by 21 publications

References 33 publications

Amniotic Fluid-Derived Stem Cells Demonstrated Cardiogenic Potential in Indirect Co-culture with Human Cardiac Cells

Amniotic Fluid-Derived Stem Cells Demonstrated Cardiogenic Potential in Indirect Co-culture with Human Cardiac Cells

21st Century Cardio-Oncology

Stem Cells in Pharmaceutical Biotechnology

Contact Info

Product

Resources

About